KR900005987A - 일부민 제제 및 이의 제조방법 - Google Patents

일부민 제제 및 이의 제조방법 Download PDF

Info

Publication number
KR900005987A
KR900005987A KR1019890015661A KR890015661A KR900005987A KR 900005987 A KR900005987 A KR 900005987A KR 1019890015661 A KR1019890015661 A KR 1019890015661A KR 890015661 A KR890015661 A KR 890015661A KR 900005987 A KR900005987 A KR 900005987A
Authority
KR
South Korea
Prior art keywords
polymer
albumin
solution
affinity chromatography
forming factor
Prior art date
Application number
KR1019890015661A
Other languages
English (en)
Other versions
KR100201195B1 (ko
Inventor
야스시 마쓰오카
신이치로 하세
가즈오 다케치
신지 도미오카
가즈마사 요코야마
Original Assignee
원본미기재
가부시키가이샤 미도리쥬지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26451019&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR900005987(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 원본미기재, 가부시키가이샤 미도리쥬지 filed Critical 원본미기재
Publication of KR900005987A publication Critical patent/KR900005987A/ko
Application granted granted Critical
Publication of KR100201195B1 publication Critical patent/KR100201195B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0023—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

내용 없음

Description

일부민 제제 및 이의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 α1-산 당단백질에 대한 1차 면역 확산에 의해 수득된 표준 곡선이다.
제2도는 합토글로빈(haptoglobin)에 대한 1차 면역 확산에 의해 수득된 표준 곡선이다.
제3도는 프리알부민에 대한 1차 면역 확산에 의해 수득된 표준 곡선이다.

Claims (9)

  1. 혈청 알부민 함량을 기준으로 하여, 3중량% 이하의 중합체 성분 및 검출 한계 이하의 α1-AGP 성분을 갖는 알부민 제제.
  2. 혈청 알부민 수용액을, 용액 중에 존재하는 중합체-형성 인자를 제거하는 단계에 적용시키고 이어서 그 용액을, 바이러스를 불활성시키기에 충분한 정도로, 열처리함을 특징으로 하여, 알부민 제제를 제조하는 방법.
  3. 제2항에 있어서, 중합체-형성 인자 제거 단계를 음이온 교환기를 사용하는 이온 교환 분리 및 친화성 크로마토그래피 중 적어도 한가지 방법으로 수행하는 방법.
  4. 제3항에 있어서, 이온 교환 분리 또는 친화성 크로마트로그래피를 컬럼 시스템으로 수행하는 방법.
  5. 제2항에 있어서, 음이온 교환기를 사용하는 방법.
  6. 제2항에 있어서, 중합체-형성 인자에 대해 특이적 친화성을 갖는 물질을 사용한 친화성 크로마토그래피를 사용하는 방법.
  7. 제6항에 있어서, 특이적 친화성 물질이 합토글로빈(haptoglobin) 및 α1-AGP에 대해 특이적 친화성을 갖는 물질을 하나 이상 함유하는 방법.
  8. 제4항에 있어서, 뱃치 시스템으로 수행하는 방법.
  9. 제2항에 있어서, 알부민보다 낮은 등전점을 갖는 단백질을 제거시키는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890015661A 1988-10-31 1989-10-31 알부민 제제 및 이의 제조방법 KR100201195B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP63-277082 1988-10-31
JP27708288 1988-10-31
JP88-277082 1988-10-31
JP11168189A JP3554796B2 (ja) 1988-10-31 1989-04-28 アルブミン製剤及びその製造方法
JP89-111681 1989-04-28

Publications (2)

Publication Number Publication Date
KR900005987A true KR900005987A (ko) 1990-05-07
KR100201195B1 KR100201195B1 (ko) 1999-06-15

Family

ID=26451019

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890015661A KR100201195B1 (ko) 1988-10-31 1989-10-31 알부민 제제 및 이의 제조방법

Country Status (7)

Country Link
EP (1) EP0367220B1 (ko)
JP (1) JP3554796B2 (ko)
KR (1) KR100201195B1 (ko)
AU (1) AU624436B2 (ko)
CA (1) CA2001911A1 (ko)
DE (1) DE68928527T2 (ko)
ES (1) ES2110947T3 (ko)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0768137B2 (ja) * 1989-06-15 1995-07-26 株式会社ミドリ十字 アルブミン製剤及びその製法
US5250662A (en) * 1989-10-05 1993-10-05 Alpha Therapeutic Corporation Albumin purification
CA2022165C (en) * 1989-10-05 1999-11-23 Chong E. Chang Albumin purification
JP2949846B2 (ja) * 1990-11-30 1999-09-20 吉富製薬株式会社 アルブミン製剤の保存方法
FR2672604B1 (fr) * 1991-02-07 1995-05-05 Pasteur Merieux Serums Vacc Procede pour isoler de l'albumine humaine a partir du surnageant iv, notamment iv-4, ou de la fraction v de cohn ou d'un surnageant ou fraction analogue.
FR2690444B1 (fr) * 1992-04-22 1995-07-13 Rucheton Marcel Procede de preparation d'une solution d'albumine plasmatique purifiee.
US5521287A (en) * 1992-05-20 1996-05-28 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same
US5440018A (en) * 1992-05-20 1995-08-08 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same
JPH07102148B2 (ja) * 1992-05-20 1995-11-08 株式会社ミドリ十字 遺伝子操作により得られるヒト血清アルブミンの製造方法、およびそれにより得られるヒト血清アルブミン含有組成物
US5728553A (en) * 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
JPH07126182A (ja) * 1993-10-27 1995-05-16 Green Cross Corp:The 組換えヒト血清アルブミン製剤の滅菌方法
AUPM388494A0 (en) * 1994-02-16 1994-03-10 Csl Limited Process for removing endotoxins
JP3702474B2 (ja) * 1994-06-01 2005-10-05 三菱ウェルファーマ株式会社 血清アルブミン製剤の製造方法
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
JP4798832B2 (ja) * 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 ヒト血清アルブミン多量体の除去方法
US7252799B2 (en) 2001-08-31 2007-08-07 Clearant, Inc. Methods for sterilizing preparations containing albumin
RS20050401A (en) * 2002-11-25 2007-06-04 Octapharma Ag., Prekallikrein depleted plasma derived albumin fraction
ES2543978T3 (es) * 2003-04-09 2015-08-26 The Chemo-Sero-Therapeutic Research Institute Proceso para la producción de una preparación de albúmina
GB0423196D0 (en) 2004-10-19 2004-11-24 Nat Blood Authority Method
ES2294976B1 (es) * 2007-11-12 2008-12-16 Grifols, S.A. "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2537123A1 (de) * 1975-08-20 1977-03-03 New Zealand Inventions Dev Verfahren zur herstellung von albumin
SE405549B (sv) * 1975-10-09 1978-12-18 Pharmacia Fine Chemicals Ab Forfarande for isolering av albumin ur plasmaprodukter genom kromatografisk fraktionering
US4043997A (en) * 1976-05-28 1977-08-23 Cutter Laboratories, Inc. Method for isolating albumin using insoluble supports coupled to a dye
US4075197A (en) * 1976-09-20 1978-02-21 Monsanto Company Serum albumin production
US4228154A (en) * 1979-02-26 1980-10-14 Armour Pharmaceutical Company Purification of plasma albumin by ion exchange chromatography
FR2543448A1 (fr) * 1983-04-01 1984-10-05 Rhone Poulenc Spec Chim Procede de fractionnement du plasma
DE3344656A1 (de) * 1983-12-09 1985-06-13 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Verfahren zur herstellung einer serumproteinloesung

Also Published As

Publication number Publication date
AU4394389A (en) 1990-05-03
AU624436B2 (en) 1992-06-11
DE68928527T2 (de) 1998-05-28
EP0367220B1 (en) 1998-01-07
KR100201195B1 (ko) 1999-06-15
DE68928527D1 (de) 1998-02-12
EP0367220A3 (en) 1991-10-09
ES2110947T3 (es) 1998-03-01
CA2001911A1 (en) 1990-04-30
JP3554796B2 (ja) 2004-08-18
JPH02191226A (ja) 1990-07-27
EP0367220A2 (en) 1990-05-09

Similar Documents

Publication Publication Date Title
KR900005987A (ko) 일부민 제제 및 이의 제조방법
Edelstein et al. On the Subunit Structure of the Protein of Human Serum High Density Lipoprotein: I. A Study of Its Major Polypeptide Component (Sephadex, Fraction III)
Hudson et al. Studies on the native and reduced alkylated renal glomerular basement membrane: Solubility, subunit size, and reaction with cyanogen bromide
Knight Jr Interferon: purification and initial characterization from human diploid cells.
Mishiro et al. A 49,000-dalton polypeptide bearing all antigenic determinants and full immunogenicity of 22-nm hepatitis B surface antigen particles.
Capaldi et al. Changes in order of migration of polypeptides in complex III and cytochrome C oxidase under different conditions of SDS polyacrylamide gel electrophoresis
KR900701823A (ko) 혈장단백질의 크로마토그래피 분리법
IE792247L (en) Interferon purification
Maddy A critical evaluation of the analysis of membrane proteins by polyacrylamide gel electrophoresis in the presence of dodecyl sulphate
ES2146600T3 (es) Condroitinasa, procedimiento para su preparacion y composicion farmaceutica.
Salton et al. Subunit structure and properties of two forms of adenosine triphosphatase released from Micrococcus, lysodeikticus membranes
Giorgio Jr et al. Thyroxine-Protein Interactions: V. ISOLATION AND CHARACTERIZATION OF A THYROXINE-BINDING GLOBULIN FROM HUMAN PLASMA
Chang et al. Purification and some physicochemical properties of staphylococcal enterotoxin D
DK0512011T3 (da) Blodfaktorer fremstillet ved rekombinant DNA-teknologi, fremgangsmåde til ekspression af blodfaktorerne samt vacciniavirusrekombinanter anvendt ved fremgangsmåden
Ralston The isolation of aggregates of spectrin from bovine erythrocyte membranes
KR870010188A (ko) 핵산 또는 엔도톡신의 제거제 및 제거방법
FR2548670B1 (fr) Procede de preparation des principales proteines du sang hemolyse sous forme non denaturee
DE3853224D1 (de) Produktion von Proteinen in aktiver Form.
Javaid et al. Association of glycoproteins with the membranes. I. Isolation and molecular weight of the monomeric unit of the major glycoprotein from human erythrocytes
Paus α‐Mannosidase from Phaseolus vulgaris: Composition and Structural Properties
Azuma et al. Heterogeneity of a human erythrocyte membrane glycoprotein
Eppstein et al. Characterization and serology of the matrix protein from a nuclear-polyhedrosis virus of Trichoplusia ni before and after degradation by an endogenous proteinase
Josephson et al. Gel isoelectric focusing of selected bovine immunoglobulins
Quinn et al. Detection and Isolation of Multiple Myoglobins from Beef Muscle a
Tashiro et al. Characteristics of cerebral non‐histone chromatin proteins as revealed by polyacrylamide gel electrophoresis

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20020307

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee